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Question: What is the retention of improvements 24 months 
after a 2-week constraint-induced movement therapy 
(CIMT) intervention in stroke survivors? Design: Follow-
up 24 months after a single blind, cross over, randomised 
controlled trial of CIMT. This paper reports follow-
up data for the intervention group that received CIMT 
without delay only. Setting: Seven US academic clinical 
sites. Participants: 106 out of 222 participants with mild 
to moderate post-stroke impairment who had experienced 
the stroke in the previous 3 to 9 months. Interventions: 
CIMT was delivered for two weeks. During the two weeks, 
participants wore a padded protective mitt that covered their 
less impaired wrist and hand up to 6 h per day, 5 days per 
week. The mitt was to be worn for 90% of waking hours. 
During that time participants did adaptive task practice 
or repetitive practice of specific tasks, such as grooming 
or eating, continuously for 15–20 minutes. Contracts with 
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Synopsis
participants and caregivers were used to promote adherence 
to mitt use. Outcomes: Primary outcomes were function 
of the paretic upper limb, measured with the Wolf Motor 
Function Test (WMFT) and the Motor Activity Log (MAL) 
measured at 12, 12.5, 16, 20, and 24 months. Health-related 
quality of life, measured with the Stroke Impact Scale (SIS), 
was a secondary outcome assessed at 12, 16, and 24 months. 
WMFT is a laboratory-based measure of upper limb motor 
function that consists of 15 timed movement tasks and two 
strength-based tasks. The MAL is a structured interview that 
assesses 30 activities of daily living on a 6-point scale when 
using the paretic arm. Results: 34% of the participants who 
received CIMT immediately after allocation had dropped 
out at 24 months. From month 12 to month 24, the time 
taken to complete the WMFT did not decline significantly 
(mean difference 0.32 s longer, 95% CI –3.06 to 3.70). Over 
the same period, outcomes improved for weight lifted in 
the WMFT (1.39 kg, 95% CI 0.04 to 2.74) and for WMFT 
grip strength (4.39 kg, 95% CI 1.86 to 6.91). There were no 
significant differences in the amount of use in the MAL 
(0.17, 95% CI –0.04 to 0.38) and how well the limb was 
used in the MAL (0.14, 95% CI –0.06 to 0.34). Conclusion: 
Outcomes that had improved significantly 12 months after 
a 2-week CIMT program were maintained for an additional 
year.
Commentary
Since the 1990s, CIMT has been examined in several 
small trials and in the large multisite EXCITE trial (Wolf 
et al 2006). The results from the EXCITE trial showed 
significantly greater functional improvement for the 
CIMT group compared to the control group at 12-months 
follow-up. The aim of the present study was to evaluate the 
retention of the treatment effect 24 months after CIMT. The 
authors conclude that the functional improvements found at 
12-months follow-up were retained for an additional year.
In our view, retention of the treatment effect has not 
been evaluated because there was no comparison against 
a control group in the present report from this study. In 
addition, the paper does not define ‘partially analysed’ and 
‘changed condition’ in the trial flow diagram, and this may 
cause bias if some participants’ data were not included in 
the analysis because their condition had worsened. Finally, 
the functional ability scale on the Wolf Motor Function 
Test showed no significant differences between the groups 
at 12-month follow-up, and it is appropriate to ask why this 
scale is excluded from the present analysis. In summary, 
these methodological shortcomings question the validity of 
the authors’ conclusion.
However, if CIMT is superior to standard treatment in 
the long run, this might be explained by motor learning 
mechanisms and corresponding motor network changes, 
as repetitive use alone is unlikely to induce long-lasting 
changes in cortical networks (Nudo 2006). This topic 
should be investigated further.
The optimal time for this treatment to be applied after 
the onset of stroke is not determined in this report. In the 
overall EXCITE trial, however, CIMT was given with 
a one-year delay to the control group. This provides the 
opportunity to compare the effect of this treatment given 
at two different time points. We look forward to publication 
of this comparison. Although a lot of questions remain 
unanswered about the efficacy of CIMT, the EXCITE trial 
has renewed the hope for stroke survivors and moved the 
research of stroke rehabilitation into the area of evidence-
based treatments.
Torunn Askim 
Norwegian University of Science and Technology, Norway
Bent Indredavik 
Trondheim University Hospital, Norway
References
Wolf SL et al (2006) JAMA 296: 2095–2104.
Nudo RJ (2006) Neurotherapeutics 3: 420–427.
